These finding are in accordance with the previous research indicating that EMPA effectively reduced inflammation through shutting down of the NF-κB pathway in several disease models such as ulcerative colitis [45] and streptozotocin-induced diabetes [46]. Here, NFKB1 is linked to diabetes mellitus.